New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:36 EDTBINDBIND Therapeutics reports Q4 EPS (50c), consensus (41c)
Reports Q4 revenue $2.07M, consensus $3.24M. Reports research and development expenses totaled $7.4M for Q4.
News For BIND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
08:43 EDTBINDBIND Therapeutics data encouraging, says JMP Securities
JMP Securities believes that data for BIND's BIND-014 showed encouraging evidence of activity and overall survival in difficult-to-treat subsets of non-small cell lung cancer. The firm reiterates a $30 price target and Outperform rating on BIND.
November 19, 2014
07:03 EDTBINDBIND Therapeutics says BIND-014 met primary objective in Phase 2 study
Subscribe for More Information
November 18, 2014
07:20 EDTBINDEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use